Enter inventor name

Grant E Gallagher

USPTO Granted Patents = 25 (Patent Applications = 4)

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 78(Granted Patents)

Location History:

Hamilton, NJ (US) (2012 - 2014)
Milltown, NJ (US) (2012 - 2024)

Company Filing History:

19 out of 75

Medical Diagnostic Laboratories, LLC

patents

2 out of 1,455

Rutgers, the State University of New Jersey

patents

2 out of 8

Venenum Biodesign, LLC

patents

4. 2 out of 832,843

Other

patents

Years Active: 2012-2024

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11883420 - Sting agonists for treating bladder cancer and solid tumors (2024-01-30),

2. RE49026 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof (2022-04-11),

3. 11110106 - Sting agonists for treating bladder cancer and solid tumors (2021-09-07),

4. 10596228 - Methods for increasing levels of interferon activity with an interferon lambda 3 polypeptide (2020-03-24),

5. 10416172 - Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling (2019-09-17),

6. 10144974 - Methods and reagents that specifically detect, distinguish and quantify IFN-LAMBDA2 mRNA from IFN-LAMBDA3 mRNA in humans (2018-12-04),

7. 9907832 - Method for increasing interferon activity in an individual (2018-03-06),

8. 9868776 - Anti-sense oligonucleotides targeted against exon 9 of IL-23R-alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases (2018-01-16),

9. 9850489 - Repressor on IFN-λ promoter and siRNA against GATA1, EVI1, and CRX to alter IFN-λ gene activity (2017-12-26),

10. 9605027 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof (2017-03-28),

11. 9523073 - Elisa for a naturally-occurring soluble truncated form of IL-23 receptor (2016-12-20),

12. 9506066 - Repressor on IFN-λ promoter and siRNA against GATA1, EVI1, and CRX to alter IFN-λ gene activity (2016-11-29),

13. 9464321 - Methods and reagents that specifically detect, distinguish and quantify IFN-λ2 mRNA from IFN-λ3 mRNA in humans (2016-10-11),

14. 9187750 - Anti-sense oligonucleotides targeted against exon 9 of IL-23Rα gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases (2015-11-17),

15. 9169292 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof (2015-10-27),

Title: Grant E. Gallagher: Innovator in Bladder Cancer and Immune Response Treatments

Introduction: Grant E. Gallagher is a distinguished inventor based in Hamilton, NJ, recognized for his significant contributions to the field of medical research and drug development. With an impressive portfolio of 25 patents, Gallagher has dedicated his career to innovating solutions that address critical health challenges.

Latest Patents: Among his most recent patents are groundbreaking methods for treating bladder cancer and solid tumors. These methods involve the administration of specific pharmaceutical compounds demonstrated to have efficacy in combating these diseases. Additionally, Gallagher has developed innovative polypeptides that bind to the IL-23 receptor, inhibiting its cell signaling pathway. This invention targets various immune-related diseases, including inflammatory bowel diseases, psoriasis, and multiple sclerosis, showcasing Gallagher's commitment to advancing therapeutic options for patients.

Career Highlights: Gallagher's career has been marked by his tenure at influential organizations, including Medical Diagnostic Laboratories, LLC, and Rutgers, the State University of New Jersey. His experience in these institutions has provided him with the resources and collaborative environment to innovate and patent his medical discoveries.

Collaborations: Throughout his career, Gallagher has collaborated with notable colleagues such as Raymond Yu and Joyce Eskdale. These partnerships have contributed to the development of new methodologies and treatments, further establishing Gallagher's reputation as a leading inventor in his field.

Conclusion: Grant E. Gallagher’s innovative spirit and dedication to medical advancements have led to numerous patents that provide hope for effective treatments in oncology and immune diseases. His work continues to influence the landscape of medical research, driving progress toward improved patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com